“The GeneEd website was created by the National Library of Medicine (NLM), the National Human Genome Research Institute (NHGRI), and the National Institutes of Health (NIH) as a helpful resource for the teaching and learning of genetics. On the site, visitors can find labs and experiments, fact sheets, and teacher resources on topics including DNA forensics, genetic conditions, evolution, and biostatistics. First-time visitors will want to start their journey by looking over the Topics tab at the top of the page. There are 40 different thematic areas here consisting of articles, video clips, webcasts, and links to additional quality resources vetted by the GeneEd web team. The Labs & Experiments section includes virtual labs that explore the genetics of different organisms as well as links to resources provided by the Howard Hughes Medical Institute and Cold Spring Harbor Laboratory. Young people may also wish to take a look at the Careers in Genetics section as it features interviews with scientists that will inspire and delight.”
Source: The Scout Report — Volume 19, Number 32 (HTML) Univ. Wisconsin
New Rochelle, NY, October 3, 2011— Genetic Engineering & Biotechnology News(GEN) celebrates 30 years as the world’s first and most widely read magazine for the biotechnology industry. Universally heralded as the definitive information source in this field, GEN covers the technology, trends, products, services, and advances that shape and drive the industry forward. GEN’s 130-page commemorative issue features articles written by luminaries, and an original poster that tracks the milestones that have altered the course of biotechnology, leading to today’s most groundbreaking scientific and therapeutic discoveries.
The nerve center of Nimbus Discovery, a largely virtual biotech start-up, resides in the offices of Atlas Venture in Cambridge, MA. Bruce Booth, an Atlas partner and chairman of the small company, recently to talked to me at the firm’s offices about how Nimbus is making use of computer-aided drug discovery software from Schrödinger to advance a pipeline of potential treatments for cancer, obesity other conditions.
Microsoft ($MSFT) chairman Bill Gates was announced as one of Nimbus’ seed investors in March, raising the profile of the young firm and shedding light on its unique relationship with Schrödinger, in which Gates invested last year through his Cascade Investment group. Nimbus hasn’t disclosed how much it has brought from Gates, Atlas and its other seed investors, yet more details could be in the offing; the company is planning a Series A round of funding in the near future.
Schrödinger, a global provider of chemistry simulation software for pharmaceutical companies, is a major shareholder in Nimbus. Ramy Farid, Schrödinger’s president, co-founded Nimbus with Atlas’ Booth in 2009 and sits on its board, the chairman says. The start-up has special access to Schrödinger’s software, support from the 21-year-old company’s computational chemistry experts and business expertise from Atlas.
While it’s too early to say with Nimbus’ drugs will succeed in clinical trials, the upstart has been able to show how the use of new software for understanding disease proteins and other tools have helped speed its drug discovery efforts, according to Booth. Read the full article >>“
"The Journal of Life Sciencesis a bi-monthly magazine founded in 2007. Focusing on the space ‘where science and society meet,’ the Journal offers fresh analysis and commentary about the impact of biotechnology and the other bio sciences on business, policy, and culture. The Journal’s intelligent, incisive, and skeptical editorial style helps readers keep up with the changes in the life sciences, which will soon affect nearly every aspect of modern life, from the food we eat to the way we approach diseases, clean the environment, and defend countries from terrorism.
The Journal is published by Burrill & Company and the California Healthcare Institute (CHI). Burrill & Company is a life sciences merchant bank and CHI is a nonprofit public policy research organization for California’s life sciences industry."
"Open access publisher BioMed Central, US, has announced the launch of a new, open-access journal – Biotechnology for Biofuels. Michael Himmel, Bärbel Hahn-Hägerdal, Chris Somerville, and Charles Wyman will serve as Editors-in-Chief of the journal. They will be supported by an international editorial board.
Biotechnology for Biofuels emphasises understanding and advancing the application of biotechnology and synergistic operations to improve plants and biological conversion systems for the production of fuels from lignocellulosic biomass and any related economic, environmental and policy issues. The journal features the latest cutting-edge research in the field, reviews and commentary articles from both Academia and Industry. Also, it will run a blog, dedicated to all aspects of the biofuels world.
BioMed Central will officially launch the journal at the forthcoming 30th symposium of Biotechnology for Fuels and Chemicals, in New Orleans."